Elinzanetant 60mg capsules
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Elinzanetant
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Elinzanetant on the MHRA register
Lynkuet 60mg capsules
Therapeutically similar medicines
Injectables
(4)Tablets & capsules
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
45 hours
Mechanism
Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3)…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
20%
Half-life
45 hours
[L53798]
Protein binding
99.7%
[L53798]
Volume of distribution
137 L
[L53798]
…
Metabolism
39%
[A274328]
…
Elimination
90%
[L53798]
…
Clearance
8.77 L/h
[L53798]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L53798][L54216]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 419 interactions
Multiple once daily doses up to 240 mg/day for 5 days were well tolerated. No dose limiting toxicities were observed with tested doses. In the case of overdose, the individual should be closely monitored, and supportive treatment should be considered based on signs and symptoms.
There is no specific antidote for elinzanetant.
[L53798]
Elinzanetant blocks NK-1 and NK-3 receptor signalling on these KNDy neurons, modulating neuronal activity involved in thermoregulation. Elinzanetant exhibits high affinity for human NK-1 receptors (mean K value of 0.37 nM) and NK-3 receptors (mean K value of 3.0 nM).[L53798]
How the body processes this drug — absorption, distribution, metabolism, and elimination
The Ctrough was 143.5 (81.3) µg/L.
[L53798]
The median (range) time to reach elinzanetant Cmax is 1.0 (1 to 4) hour. The absolute bioavailability of elinzanetant is 52%. Administration of elinzanetant (120 mg) after a high-fat, high-calorie meal decreased AUC0-24h and Cmax by approximately 42% and 70%, respectively, compared with administration under fasted conditions.
Tmax was delayed by about 1.5 h. The minimum effective steady state plasma concentrations (Ctrough) to ensure almost complete receptor-occupancy were not reduced by food intake.
[L53798]
[L53798]
[L53798]
[L53798]
[A274328]
These three metabolites are active and have comparable affinities for the human NK-1 and NK-3 receptors as elinzanetant. Elinzanetant covers 39% of the total exposure in human plasma, with all its metabolites expected to make up the rest.
[L53798]
[L53798]
[L53798]
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Elinzanetant
Additional database identifiers
Drugs Product Database (DPD)
27077
ChemSpider
17223178
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11526
GenAtlas
TACR1
GeneCards
TACR1
GenBank Gene Database
S62045
GenBank Protein Database
8176544
Guide to Pharmacology
360
UniProt Accession
NK1R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11528
GenAtlas
TACR3
GeneCards
TACR3
GenBank Gene Database
M89473
Guide to Pharmacology
362
UniProt Accession
NK3R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q108453435), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.